APA (7th ed.) Citation

AG, W., NV, D., T, L., PD, P., AH, P., N, S., . . . EP, W. (2022). A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ breast cancer, 8(1), 63. https://doi.org/10.1038/s41523-022-00429-7

Chicago Style (17th ed.) Citation

AG, Waks, et al. "A Prospective Trial of Treatment De-escalation Following Neoadjuvant Paclitaxel/trastuzumab/pertuzumab in HER2-positive Breast Cancer." NPJ Breast Cancer 8, no. 1 (2022): 63. https://doi.org/10.1038/s41523-022-00429-7.

MLA (9th ed.) Citation

AG, Waks, et al. "A Prospective Trial of Treatment De-escalation Following Neoadjuvant Paclitaxel/trastuzumab/pertuzumab in HER2-positive Breast Cancer." NPJ Breast Cancer, vol. 8, no. 1, 2022, p. 63, https://doi.org/10.1038/s41523-022-00429-7.